Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based medical device company focused on cardiac electrophysiology, announced the introduction of its LockeT product line into Italy following successful evaluations in France and Germany. The first procedures were performed at ASST Valle Olona Hospital under the direction of Dr. Manuela Bianchi, with the company subsequently receiving its first commercial purchase order from longtime partner Precise Srl.
Expanding Clinical Adoption Across Europe
LockeT, a Class I FDA-registered and CE Mark–approved suture retention device, is designed to facilitate secure wound closure following percutaneous venous punctures. After gaining clinical traction in France and Germany earlier this year, the device has now successfully been deployed in Italy. The initial cases at ASST Valle Olona Hospital further demonstrated LockeT’s clinical value, highlighting ease of use and efficiency in supporting wound closure. The subsequent commercial order from Precise Srl marks an important milestone for Catheter Precision’s European commercialization strategy, highlighting growing acceptance of LockeT in key international markets.
Strengthening Market Momentum
David Jenkins, CEO of Catheter Precision, commented on the expansion:
“The introduction of LockeT into Italy represents another meaningful step in our European rollout. With successful adoption in France and Germany and now the first commercial order in Italy, LockeT is building momentum across the continent. These early wins reinforce our belief that LockeT addresses a significant clinical and economic need, while advancing our mission to provide cost-effective, easy-to-use solutions that improve patient care.”
About Catheter Precision, Inc.
Catheter Precision, Inc. is a U.S.-based medical device company developing and commercializing innovative technologies for the cardiac electrophysiology market. Its product portfolio is designed to improve the safety, efficiency, and effectiveness of electrophysiology procedures. The company’s solutions address critical unmet needs in the treatment of cardiac arrhythmias, with LockeT serving as its flagship product for secure wound closure post-catheter ablation.
For more information, visit www.catheterprecision.com or follow Catheter Precision on LinkedIn for updates.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Catheter Precision Introduces LockeT Product Line in Italy, Expanding European Market Presence appeared first on PRISM MarketView.
